Answers are grounded in this paper and cite their sources.
Retrospective analysis demonstrates prolonged review times for medical device 510(k) filings after government shutdowns, highlighting regulatory vulnerability to operational disruptions.
Government shutdowns may impose indirect regulatory costs on medical device manufacturers by disrupting FDA review processes. This study examines changes in 510(k) review durations surrounding the 2013 and 2018 U.S. government shutdowns. We identify significant increases in post-shutdown review times and distinct timing-dependent effects across shutdowns, highlighting the sensitivity of regulatory review timelines to operational disruptions and suggest that even partial shutdowns impede medical device review timelines.
No takes yet. Share an insight, caveat, or question.
Schumacher et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: